Skip to main content

The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615188856/en/

Source: FactSet; total stockholder return graph from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial non-binding proposal to acquire the Company.

Source: FactSet; total stockholder return graph from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial non-binding proposal to acquire the Company.

“When Seer filed its proxy statement, the Board issued a 4,000-word letter to stockholders that we believe was a collection of inaccurate and misleading statements. In fact, the letter ended with the claim that Seer has the right Board and the right strategy.

Seer’s share price is down 97% since its IPO in December of 2020.1 If Seer had the right Board and the right strategy, would the share price be down 97% over the past five and a half years?

We believe change at Seer is urgently needed. The 97% share price decline supports that conclusion. And the fact that Seer Chair and CEO Omid Farokhzad, M.D. has consistently destroyed stockholder value across numerous companies adds to our view that change is urgently needed.”

Chairman and CEO Farokhzad: A Specialist in Failure

Company

Investor Outcome

Seer

Share price declined 97.0% since going public in 2020.2

BIND Therapeutics, Inc.

Filed for Chapter 11 bankruptcy protection.

Selecta Biosciences, Inc.

Share price declined 93.7% between its IPO and its merger with Cartesian Therapeutics.3

Tarveda Therapeutics, Inc.

Liquidated under a court-supervised assignment of assets.

Senti Biosciences Holdings, Inc.

Share price is down 98.5% since its public listing in 2022.4

More Than $1 Billion in Investor Capital Destroyed

The Radoff-JEC Group is seeking stockholder support to elect three new independent, qualified directors – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – to SEER’s Board at the Annual Meeting of Stockholders on July 28, 2026.

***

Vote FOR the Radoff-JEC Group’s Nominees TODAY to Prevent Further Value Destruction

Do NOT Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar.

Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.

Visit www.SaratogaProxy.com/SEER to learn more.

***

1 Share price decline from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial non-binding proposal to acquire the Company.

2 Ibid.

3 Share price decline from June 22, 2016 through November 13, 2023.

4 Share price decline from June 9, 2022 through June 12, 2026.

 

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.84
+7.28 (3.05%)
AAPL  295.87
+4.74 (1.63%)
AMD  548.77
+37.20 (7.27%)
BAC  56.14
+0.12 (0.21%)
GOOG  367.08
+8.92 (2.49%)
META  592.14
+25.16 (4.44%)
MSFT  397.87
+7.13 (1.82%)
NVDA  209.62
+4.43 (2.16%)
ORCL  193.91
+9.78 (5.31%)
TSLA  409.26
+2.83 (0.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.